- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07948161
Multisensory Room Therapy for Stress and Sensory Regulation in Children With Autism and Their Caregivers
Multidimensional Study of Child and Parental Stress in Autism Spectrum Disorder After a Multisensory Intervention: Biomarkers, Sensory Responses and Clinical Assessment. A Randomised Controlled Trial
The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).
Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.
Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.
Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.
Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.
Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: SERGIO MONTERO-NAVARRO, PhD
- Telefoonnummer: 67604 +34965426486
- E-mail: sergio.montero@uchceu.es
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria (children):
- Clinical diagnosis of autism spectrum disorder, support level 2 or 3 (DSM-5).
- Age 3 to 12 years.
- Attending and registered at the Centre de Teràpia Interfamiliar.
- Stable therapeutic and pharmacological treatment during the study period.
- Able to tolerate entering and remaining in the multisensory room.
- Written informed consent from parents or legal guardians.
Exclusion Criteria (children):
- Uncontrolled epilepsy.
- Recent changes in medication.
- Acute illness at the time of assessment.
- Severe motor or sensory disability preventing participation in the intervention.
- Persistent refusal of, or inability to adapt to, the multisensory room.
Inclusion Criteria (caregivers):
- Adult (18 years or older) main caregiver of an enrolled child.
- Sufficient cognitive capacity to understand the informed consent.
Exclusion Criteria (caregivers):
- Acute illness at the time of assessment.
- Severe motor or sensory disability preventing participation in the assessments.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Multisensory room therapy
Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples. |
Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.
Andere namen:
|
|
Actieve vergelijker: Standard behavioural therapy
Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments. |
45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)
Tijdsspanne: Baseline and week 8
|
Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome). |
Baseline and week 8
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)
Tijdsspanne: Baseline and week 8
|
Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome). |
Baseline and week 8
|
|
Change in emotional and behavioural problems (SENA, Global Problems Index)
Tijdsspanne: Baseline and week 8
|
Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: >70). Higher scores indicate more emotional and behavioural problems (worse outcome). |
Baseline and week 8
|
|
Parenting stress (PSI-SF)
Tijdsspanne: Baseline and week 8
|
PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress. |
Baseline and week 8
|
|
Child salivary cortisol (ng/mL)
Tijdsspanne: Baseline and before/after each session, weeks 1-8
|
ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system) |
Baseline and before/after each session, weeks 1-8
|
|
Child salivary oxytocin (pg/mL)
Tijdsspanne: Baseline and before/after each session, weeks 1-8
|
ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system) |
Baseline and before/after each session, weeks 1-8
|
|
Child salivary pro-inflammatory cytokines
Tijdsspanne: Baseline and before/after each session, weeks 1-8
|
Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA). |
Baseline and before/after each session, weeks 1-8
|
|
Caregiver stress biomarkers - Salivary cortisol (ng/mL)
Tijdsspanne: Baseline and week 8
|
Baseline and week 8
|
|
|
Caregiver stress biomarkers - oxytocin (pg/mL)
Tijdsspanne: Baseline and week 8
|
Baseline and week 8
|
|
|
Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)
Tijdsspanne: Baseline and week 8
|
Baseline and week 8
|
|
|
Caregiver stress biomarkers - hair cortisol (pg/mg)
Tijdsspanne: Baseline and week 8
|
Baseline and week 8
|
|
|
In-session self-regulation (observational record)
Tijdsspanne: After each session, weeks 1-8
|
Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty. |
After each session, weeks 1-8
|
|
Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device
Tijdsspanne: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
|
Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device
Tijdsspanne: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
|
Breathing rate (breaths per minute). BIOPAC MP36R device
Tijdsspanne: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
|
Skin temperature (ºC). BIOPAC MP36R device
Tijdsspanne: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse events
Tijdsspanne: Weeks 1-8
|
Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group. |
Weeks 1-8
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CEEI26/863
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .